MedTrace Logo

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01509339 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-01-12

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis.

Conditions

Interventions

DRUG

Vancomycin

250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Case Western Reserve University

    lead OTHER

Principal Investigators

  • Elliott C Dasenbrook, MD MHS · Case Western Reserve University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2021-12-23
Completion
2021-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509339 on ClinicalTrials.gov